Park Place Capital Corp Buys 844 Shares of DexCom, Inc. (NASDAQ:DXCM)

Park Place Capital Corp boosted its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 3,516.7% in the fourth quarter, HoldingsChannel reports. The firm owned 868 shares of the medical device company’s stock after purchasing an additional 844 shares during the quarter. Park Place Capital Corp’s holdings in DexCom were worth $68,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Blue Whale Capital LLP boosted its position in DexCom by 91.9% during the third quarter. Blue Whale Capital LLP now owns 236,000 shares of the medical device company’s stock worth $15,821,000 after purchasing an additional 113,000 shares during the period. Taylor Frigon Capital Management LLC lifted its holdings in shares of DexCom by 51.6% during the third quarter. Taylor Frigon Capital Management LLC now owns 32,554 shares of the medical device company’s stock worth $2,182,000 after buying an additional 11,075 shares in the last quarter. Brooktree Capital Management acquired a new stake in shares of DexCom during the third quarter worth $683,000. National Pension Service lifted its holdings in shares of DexCom by 4.1% during the third quarter. National Pension Service now owns 949,743 shares of the medical device company’s stock worth $63,671,000 after buying an additional 37,363 shares in the last quarter. Finally, Intact Investment Management Inc. acquired a new stake in shares of DexCom during the third quarter worth $650,000. 97.75% of the stock is owned by institutional investors.

DexCom Price Performance

DexCom stock opened at $87.09 on Thursday. The stock has a market capitalization of $34.02 billion, a price-to-earnings ratio of 52.15, a PEG ratio of 2.21 and a beta of 1.12. DexCom, Inc. has a 52-week low of $62.34 and a 52-week high of $142.00. The stock’s 50 day moving average price is $78.70 and its two-hundred day moving average price is $77.37. The company has a debt-to-equity ratio of 1.23, a quick ratio of 2.12 and a current ratio of 2.46.

Insider Buying and Selling

In related news, EVP Sadie Stern sold 4,259 shares of the stock in a transaction on Wednesday, November 20th. The stock was sold at an average price of $74.73, for a total value of $318,275.07. Following the transaction, the executive vice president now directly owns 71,192 shares in the company, valued at $5,320,178.16. This trade represents a 5.64 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.30% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of research analysts recently commented on DXCM shares. Robert W. Baird raised DexCom from a “neutral” rating to an “outperform” rating and boosted their price target for the company from $86.00 to $104.00 in a research note on Thursday, January 16th. Leerink Partners cut their price objective on shares of DexCom from $90.00 to $87.00 and set an “outperform” rating for the company in a research report on Friday, October 25th. JPMorgan Chase & Co. upped their price objective on shares of DexCom from $75.00 to $85.00 and gave the stock a “neutral” rating in a research report on Friday, October 25th. Oppenheimer cut their price objective on shares of DexCom from $115.00 to $105.00 and set an “outperform” rating for the company in a research report on Friday, October 25th. Finally, Wells Fargo & Company upped their price objective on shares of DexCom from $90.00 to $94.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 11th. Five analysts have rated the stock with a hold rating, twelve have given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $99.29.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.